PI Industries Limited has released the transcript of its earnings conference call held on Wednesday, August 12, 2026. The discussion covered the unaudited standalone and consolidated financial results for the quarter ended June 30, 2026, which saw a 39% year-on-year decline in consolidated net profit to ₹2,442 Mn.

The filing was made pursuant to Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The transcript is available on the company's website for investors and analysts to review.

Financial Performance Breakdown

The financial deterioration reported in the quarter was primarily driven by the export business, which constitutes the majority of revenue. Export revenue dropped 13.3% to ₹13,542 Mn due to an 8% volume decline in agchem exports. In contrast, domestic revenue grew 2.8% to ₹3,481 Mn, supported by a ~12% volume increase, largely propelled by the biologicals segment which expanded over 50% year-on-year. However, overall gross margins slipped by 69 basis points to 57%, impacted by rising raw material prices linked to geopolitical tensions.

Segmental Insights: Agchem vs. Pharma

The Agrochemicals segment, which includes CSM exports, domestic agri brands, and biologicals, generated segment revenue of ₹16,488 Mn, down from ₹18,287 Mn in Q1FY26. Profit before tax for this segment fell to ₹3,835 Mn from ₹5,656 Mn. Challenges included generic competition and delayed monsoon patterns affecting Kharif sowing in India. Overheads increased by 5% to ₹5,984 Mn.

The Pharma segment, comprising PI Health Sciences (PIHS), saw revenue contract by 25% to ₹542 Mn, attributed to order book phasing and customer delivery schedules rather than structural issues. PIHS posted a pre-tax loss of ₹816 Mn, widening from ₹760 Mn in Q1FY26. Despite the near-term slowdown, management noted positive developments in the innovation pipeline, including three new molecules commercialized in exports and a new peptide-based biological product launched in the US.

Cash Flow and Balance Sheet Strength

A critical analytical observation is the divergence between operating cash flow and net profit. While net profit fell sharply, cash flow from operating activities stood at a robust ₹6,395 Mn in Q1FY27. This indicates that the profit decline was not accompanied by working capital strain; instead, the company improved trade working capital efficiency, reducing it by 19 days to 120 days. This liquidity strength positions PI Industries to navigate the cyclical downturn without compromising its investment pipeline.

PI Industries maintained a strong financial position with shareholders' funds increasing to ₹1,14,683 Mn. The net cash balance rose to ₹37,939 Mn, providing ample capacity for future strategic investments. Total capital expenditure for Q1FY27 was ₹2,685 Mn, focused on enhancing manufacturing capabilities and R&D. The Debt/Equity ratio remained negligible at 0.02.

Strategic Developments and Analyst Queries

Looking ahead, the company plans to launch five new products in FY27 to accelerate export growth. In the health sciences segment, efforts are focused on building relationships with biotech and big pharma companies through global business development. Additionally, the Board approved the incorporation of PI Foundation under Section 8 of the Companies Act, 2013, as a wholly-owned subsidiary to carry out CSR activities in accordance with Section 135 read with Schedule VII of the Act. The initial share capital subscription for the foundation is ₹1,00,000.

During the Q&A session, management addressed several key areas:

• New Molecule Pipeline: Mayank Singhal clarified that the pipeline of approximately 90 molecules is majority within Agchem, with significant presence in biology and electronics. He highlighted Pioxaniliprole, an insecticide discovered in India, set to launch in the domestic market soon pending regulatory approvals.
• Pricing Pressure: Singhal attributed pricing pressure to challenged demand cycles, soft commodity prices, and high input costs. He noted that while generic products face pressure, PI’s differentiated portfolio helps mitigate this impact.
• Biologics Growth: Jagresh Rana detailed the global traction of the biologics platform, citing 500+ field trials and 1,000+ grower engagements. He mentioned the unique foliar application nematode product, registered in Brazil, Mexico, and the US, as a key differentiator.
• Pharma CRDMO Transition: Management emphasized the long gestation period of the CRDMO model, noting that current losses are due to front-loaded investments in regulatory frameworks and capability building. They expect volatility to reduce as the portfolio scales.
• Electronic Chemicals: Singhal confirmed that commercial supplies have started in electronic chemicals, with investments continuing to support next-generation technologies.

Source: https://lodr-files.dhan.co/lodr-inputs/Company/INE603J01030/f204967e-e1ce-496a-845c-dbbcac5fcfa7.pdf

PI Industries will interact with analysts and investors on August 19, 2026, during the Motilal Oswal 22nd Annual Global Investor Conference in Mumbai.

The company disclosed the engagement pursuant to Regulation 30(6) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The session will feature a mix of one-on-one and group meetings.

Meeting Details

The company stated that no unpublished price-sensitive information is proposed to be shared during the meeting. The schedule is subject to change due to exigencies on the part of the investors or the company.

Shruti Joshi, Company Secretary and Compliance Officer, signed the disclosure filed with BSE and NSE on August 12, 2026.